Trial Profile
Feasibility and efficacy of gemcitabine plus albumin-bound paclitaxel combination therapy (GEM+nabPTX therapy) in patients with borderline resectable pancreatic cancer in the neoadjvant setting.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 May 2016
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 14 May 2016 New trial record